Red blood cell life span and erythropoietin resistance

Kidney International

Volumn 81, Issue 12, 2012, Pages 1275-1276

  Dou, Yanna ^a,b,c   Kruse, Anja ^a,b,d   Kotanko, Peter ^a,b   Rosen, Herman ^b   Levin, Nathan W ^a,b   Thijssen, Stephan ^a,b  

^a RENAL RESEARCH INSTITUTE   (United States)

^b BETH ISRAEL MEDICAL CENTER   (United States)

^c PEKING UNIVERSITY FIRST HOSPITAL   (China)

^d UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; IRON; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; CELL FUNCTION; DRUG DOSE INCREASE; DRUG SENSITIVITY; DRUG TREATMENT FAILURE; ERYTHROCYTE COUNT; ERYTHROCYTE LIFESPAN; ERYTHROCYTE METABOLISM; ERYTHROPOIESIS; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; LETTER; PRIORITY JOURNAL; TREATMENT RESPONSE;

EID: 84861674461     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2012.54     Document Type: Letter

References (4)

1. Bamgbola OF. Pattern of resistance to erythropoietin-stimulating agents in chronic kidney disease. Kidney Int 2011; 80: 464-474.
2. Uehlinger DE, Gotch FA, Sheiner LB. A pharmacodynamic model of erythropoietin therapy for uremic anemia. Clin Pharmacol Ther 1992; 51: 76-89.
3. Kruse A, Uehlinger DE, Gotch F et al. Red blood cell lifespan, erythropoiesis and hemoglobin control. Contrib Nephrol 2008; 161: 247-254.
4. Strocchi A, Schwartz S, Ellefson M et al. A simple carbon monoxide breath test to estimate erythrocyte turnover. J Lab Clin Med 1992; 120: 392-399.